Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart, Anlotinib, and Chemotherapy in Locally Advanced Oral Cancer
NCT06848439Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in oral squamous cell carcinoma (OSCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06848439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848439.